miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression

Xu, Xiaowei; Jin, Shuai; Ma, Yongfu; Zhang, Fan; Zhang, Yan; Li, Wenchao; Song, Qi; You, Wenye; Lyu, Zhaohui; Song, Ye-Qiong; Shi, Pingan; Liu, Ying; Han, Xiao; Li, Ling; Liu, Yang; Ye, Qinong

doi:10.1007/s00109-017-1539-z

Cited by 55 publications

(44 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Downregulation of miR-205 confers glioma cells with DDP resistance and pancreatic cancer cells with gemcitabine resistance [21,22]. miR-30a influences chemoresistance in melanoma cells by targeting insulin-like growth factor 1 [23], regulates etoposide/DDP resistance in small cell lung cancer by targeting Beclin-1 [24], sensitizes NSCLC cells to paclitaxel through B-cell lymphoma 2 inhibition [25], and enables acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors to be overcome in NSCLC cells by reducing phosphoinositide-3-kinase regulatory Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry submit 2 [26]. miR-30a decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy [27].…”

Section: Discussionmentioning

confidence: 99%

Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing

Yuan

Song

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Drug resistance remains a main obstacle to the treatment of non- small cell lung cancer (NSCLC). The aim of this study was to identify the expression profiles of microRNAs (miRNAs) in drug-resistant NSCLC cell lines. Methods: The expression profiles of miRNAs in drug-resistant NSCLC cell lines were examined using miRNA sequencing, and the common dysregulated miRNAs in these cell lines were identified and analyzed by bioinformatics methods. Results: A total of 29 upregulated miRNAs and 36 downregulated miRNAs were found in the drug-resistant NSCLC cell lines, of which 26 upregulated and 36 downregulated miRNAs were found to be involved in the Ras signaling pathway. The expression levels, survival analysis, and receiver operating characteristic curve of the dysregulated miRNAs based on The Cancer Genome Atlas database for lung adenocarcinoma showed that hsa-mir-192, hsa-mir-1293, hsa-mir-194, hsa-mir-561, hsa-mir-205, hsa-mir-30a, and hsa-mir-30c were related to lung cancer, whereas only hsa-mir-1293 and hsa-mir-561 were not involved in drug resistance. Conclusion: The results of this study may provide novel biomarkers for drug resistance in NSCLC and potential therapies for overcoming drug resistance, and may also reveal the potential mechanisms underlying drug resistance in this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing

Yuan

Song

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Previous studies have defined miR-30a as a putative tumor suppressor that is frequently dysregulated in cancers including osteosarcoma and cancers of the breast, lung, and head and neck [11,[23][24][25][26][27][28]. One mechanism whereby miR-30 may modulate cancer development is via inhibiting cell proliferation and invasion and by inducing apoptotic cell death [24][25][26][27]. Indeed, miR-30a overexpression is associated with reduced BCL-2 expression in non-small-cell lung cancer, leading to the increased apoptotic death of these cells [24].…”

Section: Biomed Research Internationalmentioning

confidence: 99%

Genetic Variations in miR-30 Family Member Regulatory Regions Are Associated with Breast Cancer Risk in a Chinese Population

Zhou

Wang

Liu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

MicroRNAs (miRNAs) of the miR-30 family are closely linked with tumor metastasis and play key roles in the complex malignant phenotypes of cancers by targeting many tumor-related genes. Deregulated expression of miR-30 family members has been commonly observed in breast cancer. However, associations between the genetic variants in the regulatory region of miR-30 family and the risk of breast cancer are still limited, especially in the Chinese Han population. In the present study, we conducted a case-control analysis wherein 1064 breast cancer patients and 1073 healthy controls underwent genotyping of 10 SNPs in the regulatory region of miR-30 family members. Multivariate logistic regression analyses illustrated that the rs763354 variant in the miR-30a regulatory region was linked with a significant decrease in breast cancer risk in an additive model (adjusted OR = 0:86, 95% CI: 0.75-0.98, P = 0:022). Further, eQTL analyses also indicated that this SNP was associated with miR-30a expression levels in breast cancer samples compiled in the TCGA database (P = 0:020). The Kaplan-Meier plotter showed that breast cancer patients with higher miR-30a expression have significantly better outcomes than do patients expressing low levels of this miRNA (HR = 0:75, 95% CI: 0.61-0.91, P = 0:0041). Together, these findings suggest that the miR-30a rs763354 SNP is an important regulator of breast cancer risk, thus making it a potentially viable prognostic biomarker and one that can be used to guide therapeutic treatment in affected patients.

show abstract

“…CTGF, connective tissue growth factor; GC, gastric cancer; IRF2BP2, interferon regulatory factor 2 binding protein 2; RT-qPCR, real-time quantitative PCR; TEAD4, TEA domain family members 4; VGLL4, vestigial-like family member 4 predicted binding site in the 3′-UTR of IRF2BP2 were identified using TargetScan (http://www.targe tscan.org/) and microRNA.org (http://www.micro rna.org/). Four miRNAs (miR-101-3p, miR-30a-5p, miR-519d-3p and miR-155-5p) reported to play roles in human tumours were chosen [33][34][35][36] ( Figure 6A). The results of Western blotting in the SGC-7901 and BGC-823 cell lines showed that the overexpression of miR-101-3p significantly reduced IRF2BP2 protein expression ( Figure 6B,C); however, the overexpression of miR-101-3p had no significant effect on IRF2BP2 mRNA expression ( Figure 6D).…”

Section: Micror-101-3p Suppresses Ctgf Expression Through Irf2bp2-ymentioning

confidence: 99%

Down‐regulation of interferon regulatory factor 2 binding protein 2 suppresses gastric cancer progression by negatively regulating connective tissue growth factor

Yao

Wang

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Interferon regulatory factor 2 binding protein 2 (IRF2BP2) is a transcriptional repressor involved in regulating gene expression and other biological processes, including tumorigenesis. However, the clinical significance and roles of IRF2BP2 in human gastric cancer (GC) remain uncertain. Clinical GC tissues were obtained from GC patients at the First Affiliated Hospital of Nanchang University. Immunohistochemistry (IHC) was conducted to detect the IRF2BP2 protein in clinical paraffin specimens. Cell proliferation, migration and invasion were evaluated by MTT, colony formation assays and transwell assays. Co‐immunoprecipitation was conducted to detect the interaction between TEA domain family members 4 (TEAD4) and vestigial‐like family member 4 (VGLL4) or Yes‐associated protein 1 (YAP1). Dual‐luciferase reporter assay was used to confirm the binding of miR‐101‐3p to the 3′‐UTR. The expression of IRF2BP2 was significantly higher in GC tissues than in normal tissues. Patients with higher IRF2BP2 protein expression had lower survival. IRF2BP2 knockdown inhibited proliferation, migration, invasion and epithelial‐mesenchymal transition in GC cells. IRF2BP2 knockdown decreased the mRNA and protein levels of connective tissue growth factor (CTGF). The interaction between IRF2BP2 and VGLL4 increased the binding of TEAD4 to YAP1, resulting in the transcriptional coactivation of CTGF. In addition, miR‐101‐3p suppressed the expression of CTGF by directly targeting the 3′‐UTR of IRF2BP2. Taken together, these findings provide a model for the role of miR‐101‐3p‐IRF2BP2‐CTGF signalling axis in GC and a novel insight into the mechanism of GC progression and metastasis.

show abstract

miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression

Cited by 55 publications

References 36 publications

Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing

Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing

Genetic Variations in miR-30 Family Member Regulatory Regions Are Associated with Breast Cancer Risk in a Chinese Population

Down‐regulation of interferon regulatory factor 2 binding protein 2 suppresses gastric cancer progression by negatively regulating connective tissue growth factor

Contact Info

Product

Resources

About